|
|
Article: SR PHARMA PLC - Result of Equity Issue.
- Article from:
- PR Newswire UK Disclose
- Article date:
- July 28, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SR Pharma announces [pounds sterling]10m of new funding following a successful fundraising with
institutional investors and strategic investor, Introgen Therapeutics Inc.,
Austin Texas, USA
London, UK and Berlin, Germany, Austin, Texas USA, 28 July 2005 SR Pharma plc
(SR Pharma or the Company, AIM:SPA), the European biotechnology company which
is developing an oncology and inflammation business both internally and via
acquisition, announces that following its recent acquisition of Atugen AG, it
has raised [pounds sterling]8.3m via a placing with institutional investors. The proceeds of
the fundraising will be used to develop the products ...
Related newspaper, magazine, and journal articles:
|
|
Article: INTROGEN THERAPEUTICS ORAL HEALTH ALLIANCE WITH ...
AsiaPulse News;
November 7, 2005 ;
700+ words
... ... Cancer and Oral Premalignancies Introgen Therapeutics, Inc. (Nasdaq: INGN) today ... 241, INGN 225, and INGN 401. Introgen Therapeutics, Inc. is a biopharmaceutical ... facility. For more information on Introgen Therapeutics, or for a menu of archived press ...
|
|